Splenic Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Splenic Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas [Phase 2]
This clinical trial update summarizes the MALIBU Phase 2 study evaluating the combination of ibrutinib and rituximab in untreated marginal z…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients [Phase 3]
A Phase 3 trial is evaluating Rituximab plus Zanubrutinib versus Rituximab alone in untreated Splenic marginal zone lymphoma, with the study…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
Clinical trial to integrate molecular and clinical profiling of splenic marginal zone lymphoma (transformed form), currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 clinical trial update for epcoritamab in newly diagnosed marginal zone lymphoma, currently recruiting across MZL subtypes.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating bendamustine and rituximab for splenic marginal zone lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results …
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial evaluating BCD-020 for indolent non-Hodgkin lymphomas has completed, assessing safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2017-10-09Clinical Trial Update: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of pegfilgrastim and rituximab in patients with untreated, relapsed, or refractory follicu…
-
CLINICAL_TRIALS trial_result · 2017-09-29Clinical Trial Update: A Phase I/II Study of Intratumoral Injection of SD-101 [Phase 1, Phase 2]
Phase I/II trial investigating intratumoral SD-101 for various B-cell lymphomas; study completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
The clinical trial evaluated the BRAF V600E mutation status in chronic lymphoproliferative diseases, specifically hairy cell leukemia and sp…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia [Phase 3]
A Phase 3 trial compares chlorambucil with fludarabine in patients with advanced Waldenström macroglobulinemia. The study also covers lympho…
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial completion evaluating a fusion protein cytokine therapy after Rituximab in patients with B-cell non-Hodgkin lymphomas.
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2015-01-27Clinical Trial Update: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating rituximab, cyclophosphamide, bortezomib, and dexamethasone in relapsed/refractory low-grade follicular lym…
-
CLINICAL_TRIALS trial_result · 2014-12-23Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms…
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update evaluating the combination of iodine-131 tositumomab with fludarabine phosphate in older patients undergoing autologous…